HOPO Therapeutics, Inc.

About HOPO Therapeutics, Inc.

HOPO Therapeutics is a clinical-stage pharmaceutical company focused on developing best-in-class therapeutics to prevent and treat the toxic effects of heavy metal exposure on human health. They aim to provide safer, more effective solutions for heavy metal toxicity, addressing urgent needs for patients exposed to radioactive materials and environmental toxins.

Products & Services

HOPO-101:An orally-administered chelating agent designed to treat heavy metal toxicity.

Programs for Radiological Hazards:Focused on treatments for exposure to radioactive materials like uranium and plutonium.

Programs for Lead Poisoning:Therapeutics targeting lead exposure and toxicity.

Programs for Toxic Heavy Metals:Solutions for exposure to environmental toxins such as mercury and other heavy metals.

Specialties

Heavy Metal Toxicity Treatment Chelating Agents Radiological Hazard Solutions Lead Poisoning Treatment Toxic Heavy Metal Exposure Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Government Contract T: - FT: Government Contract	A: 226000000 MR: - FA: up to $226 million FAN: 226000000	D: 2024-10-28 FD: 2024-10-28	1 investors

Government Contract Latest

2024-10-28

$226.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Julian Rees, PhD

CEO & Co-Founder

LinkedIn (Pro only)

R

Rebecca Abergel, PhD

CSO & Co-Founder

LinkedIn (Pro only)

H

Hannah Weber

Vice President, Strategy & Business Development & Co-Founder

LinkedIn (Pro only)

J

Jody Khouri

Vice President, Program, Portfolio, & Alliance Management

M

Michelle Rose

Head of Regulatory

M

Mark Sorenson, PhD

Head of CMC Development

View 30 more team members with Pro

Unlock Full Team Directory

Recent News